Literature DB >> 12869192

Alternative binding modes of an inhibitor to two different kinases.

Erika De Moliner1, Nick R Brown, Louise N Johnson.   

Abstract

Protein kinases are targets for therapeutic agents designed to intervene in signaling processes in the diseased state. Most kinase inhibitors are directed towards the conserved ATP binding site. Because the essential features of this site are conserved in all eukaryotic protein kinases, it is generally assumed that the same compound will bind in a similar manner to different protein kinases. The inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) is a selective inhibitor for the protein kinase CK2 (IC50 1.6 micro m) (Sarno et al. (2001) FEBS Letts.496, 44-48). Three other kinases [cyclin-dependent protein kinase 2 (CDK2), phosphorylase kinase and glycogen synthase kinase 3beta] exhibit approximately 10-fold weaker affinity for TBB than CK2. We report the crystal structure of TBB in complex with phospho-CDK2-cyclin A at 2.2 A resolution and compare the interactions with those observed for TBB bound to CK2. TBB binds at the ATP binding site of both kinases. In CDK2, each of the four bromine atoms makes polar contacts either to main chain oxygens in the hinge region of the kinase or to water molecules, in addition to several van der Waals contacts. The mode of binding of TBB to CDK2 is different from that to CK2. TBB in CDK2 is displaced more towards the hinge region between the N- and C-terminal lobes and rotated relative to TBB in CK2. The ATP binding pocket is wider in CDK2 than in CK2 resulting in fewer van der Waals contacts but TBB in CK2 does not contact the hinge. The structures show that, despite the conservation of the ATP binding pocket, the inhibitor is able to exploit different recognition features so that the same compound can bind in different ways to the two different kinases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12869192     DOI: 10.1046/j.1432-1033.2003.03697.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  14 in total

1.  Molecular docking studies of protein-nucleotide complexes using MOLSDOCK (mutually orthogonal Latin squares DOCK).

Authors:  Shankaran Nehru Viji; Nagarajan Balaji; Namasivayam Gautham
Journal:  J Mol Model       Date:  2012-03-01       Impact factor: 1.810

2.  An overview of halogen bonding.

Authors:  Peter Politzer; Pat Lane; Monica C Concha; Yuguang Ma; Jane S Murray
Journal:  J Mol Model       Date:  2006-09-30       Impact factor: 1.810

3.  The structure, properties, and nature of unconventional π halogen bond in the complexes of Al4(2-) and halohydrocarbons.

Authors:  Ran Li; Qingzhong Li; Jianbo Cheng; Wenzuo Li
Journal:  J Mol Model       Date:  2011-10-05       Impact factor: 1.810

4.  Halogen bonds in biological molecules.

Authors:  Pascal Auffinger; Franklin A Hays; Eric Westhof; P Shing Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-19       Impact factor: 11.205

5.  In vitro selection and characterization of RNA aptamers binding thyroxine hormone.

Authors:  Dominique Lévesque; Jean-Denis Beaudoin; Sébastien Roy; Jean-Pierre Perreault
Journal:  Biochem J       Date:  2007-04-01       Impact factor: 3.857

Review 6.  A structural insight into CK2 inhibition.

Authors:  Marco Mazzorana; Lorenzo A Pinna; Roberto Battistutta
Journal:  Mol Cell Biochem       Date:  2008-07-15       Impact factor: 3.396

7.  Structural basis for decreased affinity of Emodin binding to Val66-mutated human CK2 alpha as determined by molecular dynamics.

Authors:  Na Zhang; Rugang Zhong
Journal:  J Mol Model       Date:  2009-10-11       Impact factor: 1.810

8.  Using halogen bonds to address the protein backbone: a systematic evaluation.

Authors:  Rainer Wilcken; Markus O Zimmermann; Andreas Lange; Stefan Zahn; Frank M Boeckler
Journal:  J Comput Aided Mol Des       Date:  2012-08-04       Impact factor: 3.686

9.  Synthesis of Novel Halogenated Heterocycles Based on o-Phenylenediamine and Their Interactions with the Catalytic Subunit of Protein Kinase CK2.

Authors:  Maria Winiewska-Szajewska; Agnieszka Monika Maciejewska; Elżbieta Speina; Jarosław Poznański; Daniel Paprocki
Journal:  Molecules       Date:  2021-05-25       Impact factor: 4.411

10.  Isomeric mono-, di-, and tri-bromobenzo-1H-triazoles as inhibitors of human protein kinase CK2α.

Authors:  Romualda Wąsik; Patrycja Wińska; Jarosław Poznański; David Shugar
Journal:  PLoS One       Date:  2012-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.